Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Tenaya Therapeutics Inc (TNYA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.32-14.57%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for TNYA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Progress in gene therapy trials and pipeline development | A primary condition in Tenaya Therapeutics Inc's published investment case. The stated target is Positive interim trial data and advancement of 15 gene targets by mid-2027. | Improving | failure to advance key gene therapy trials or pipeline targets by mid-2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 9, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is in a watch state: key clinical and regulatory work is progressing, but recent financial performance is weak and confidence in the assessment is low.
The valuation model indicates TNYA is expensive versus peers, with much of the difference tied to potential future program value rather than current earnings. The expectations gap is marked, but model confidence is low, so the valuation signal is uncertain; the evidence does not point to broad market fragility beyond the valuation premium.
Near term, losses and weak financial performance are likely to remain central because the evidence shows no established earnings base. Management is on track with TN-201 and TN-401 development and regulatory engagement, while TN-301 remains at an earlier stage. Cash was $78.1 million in 2026-Q2, and management expects funding through Q3 2027; a guidance cut or continued execution delays would add risk.
Over the next one to three years, the thesis hinges on safety and efficacy evidence for TN-201 and TN-401, progress toward pivotal trial plans, and whether TN-301 reaches planned clinical evaluation. Cash discipline and the stated runway also matter, while weaker employment data could pressure healthcare names and strong results from sector bellwethers could support sector momentum.
TNYA’s multi-year view rests on clinical progress and cash runway, not current earnings, and both execution risk and assessment uncertainty are high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain funding to support operations through mid-2027 |
| The company plans to fund operations through mid-2027 using collaboration payments. |
| Intact |
| cash runway falls short of mid-2027 funding needs |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve Nasdaq minimum bid price compliance | A supporting condition in Tenaya Therapeutics Inc's published investment case. The stated target is Compliance with Nasdaq minimum bid price rules by end of 2026. | Under Pressure | failure to regain Nasdaq compliance by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.41 → $-0.37 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.41 | $0 | 5 / 4 |
| 2026-07-25 | $-0.41 | $0 | 5 / 4 |
| 2026-07-26 | $-0.41 | $0 | 5 / 4 |
| 2026-07-27 | $-0.41 | $0 | 5 / 4 |
| 2026-07-28 | $-0.41 | $0 | 5 / 4 |
| 2026-07-29 | $-0.41 | $0 | 5 / 4 |
| 2026-07-30 | $-0.41 | $0 | 5 / 4 |
| 2026-07-31 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-01 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-02 | $-0.41 | $0 | 5 / 4 |
| 2026-08-03 | $-0.41 | $0 | 5 / 4 |
| 2026-08-04 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-05 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-06 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-08 | $-0.43 | $0 | 5 / 3 |
| 2026-08-09 | $-0.43 | $0 | 5 / 3 |
| 2026-08-10 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-12 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-13 | $-0.39 | $2,800,000 | 4 / 2 |
| 2026-08-14 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-15 | $-0.41 | $103,740,200 | 4 / 2 |
| 2026-08-16 | $-0.41 | $103,740,200 | 3 / 2 |
| 2026-08-17 | $-0.41 | $103,740,200 | 3 / 2 |
| 2026-08-18 | $-0.41 | $103,740,200 | 4 / 3 |
| 2026-08-19 | $-0.41 | $103,740,200 | 4 / 3 |
| 2026-08-20 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-21 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-22 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-23 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-24 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-25 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-26 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-27 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-28 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-29 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-30 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-08-31 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-01 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-02 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-03 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-04 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-05 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-06 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-07 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-08 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-09 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-10 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-11 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-12 | $-0.39 | $2,000,000 | 4 / 3 |
| 2026-09-13 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-14 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-15 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-16 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-17 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-18 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-19 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-20 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-21 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-22 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-23 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-24 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-25 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-26 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-27 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-28 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-29 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-09-30 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-01 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-02 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-03 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-04 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-05 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-06 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-07 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-08 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-09 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-10 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-11 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-12 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-13 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-14 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-15 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-16 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-17 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-18 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-19 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-20 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-21 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-22 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-23 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-24 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-25 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-26 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-27 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-28 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-29 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-30 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-10-31 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-11-01 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-11-02 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-11-03 | $-0.37 | $2,000,000 | 4 / 3 |
| 2026-11-04 | $-0.37 | $2,000,000 | 4 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.